Litocid

Quick links to important sections

Litocid

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Litocid

Property Description
Active ingredient Potassium Citrate (Tripotassium Citrate Monohydrate)
Form Modified Release Tablet (Extended Release) or Oral Solution
Pharmacological class Urinary Alkalinizing Agent
Common use Prevention and management of mineral deposits in the urinary tract
Origin Synthetic salt of citric acid

Litocid: A Definition and Pharmacological Classification

Litocid is a prescription-only medication primarily identified by its active ingredient, Potassium Citrate, which acts as a chemical modifier of the urine. It belongs to the Urinary Alkalinizing Agent pharmacological class, distinguishing it as an agent specifically designed to raise the pH of the urinary tract. The drug is a single-ingredient product, offering a focused therapeutic approach centered on the metabolic effects of potassium citrate, which is manufactured as a synthetic compound. Potassium Citrate is indicated for the management of conditions like hypocitraturic calcium oxalate nephrolithiasis and uric acid lithiasis. This means the medicine is clinically recognized for its role in preventing stone formation by correcting specific chemical imbalances in the urine.

Composition and Form: Potassium Citrate Delivery

The medicinal core of Litocid is Potassium Citrate, intended for oral administration, typically delivered via a specialized Modified Release Tablet or an Extended Release Tablet. The use of this controlled-release form is a differentiating feature designed to ensure the gradual release of the active component into the gastrointestinal tract. This formulation, containing specific pharmaceutical excipients, regulates the dissolution rate, which is critical for achieving a consistent therapeutic outcome while also minimizing the risk of rapid, transient pH fluctuations associated with immediate-release forms.

The General Purpose of Alkalinization and Citrate

The general purpose of Litocid is to modify the chemical environment of the urinary tract, thereby reducing the urine's susceptibility to the formation of crystalline mineral deposits. The drug accomplishes this by converting the citrate component into bicarbonate, which effectively raises the urine's pH (alkalinization), and by directly increasing the concentration of citrate in the urine. Citrate acts as a natural inhibitor, binding to calcium to prevent crystal aggregation. A typical use scenario involves taking Litocid to maintain adequate urinary pH levels as a long-term strategy against recurring stone formation.

What side effects are possible with Litocid?

Official Safety Profile and Adverse Reaction Categories

The safety profile for Litocid (Potassium Citrate) is structured by government regulatory documents based on the systems affected and the frequency of occurrence. Common adverse reactions are frequently linked to Gastrointestinal Disorders, while serious concerns primarily involve Metabolism and Nutrition Disorders and severe gastrointestinal events.

Frequency-Classified Effects

Side effects are officially classified into frequency tiers. Those considered Very Common or Common include various forms of abdominal discomfort, such as upper abdominal pain, nausea, vomiting, diarrhea, and dyspepsia (indigestion). Less frequently, skin rash has also been documented. Certain severe reactions, such as severe gastrointestinal lesions, are listed with a Not Known frequency due to their rarity in reported data.

Serious Adverse Reactions and Safety Constraints

The most clinically significant adverse reaction listed in regulatory labeling is hyperkalemia (elevated blood potassium levels), which is a serious, potentially fatal condition that can lead to Cardiac Arrest or severe cardiac conduction abnormalities. Furthermore, the extended-release formulation carries the documented risk of serious Gastrointestinal Lesions, including ulceration, bleeding, obstruction, or perforation.

The medicine is strictly contraindicated in patients with conditions that predispose them to hyperkalemia (such as severe renal impairment, adrenal insufficiency, or uncontrolled diabetes) or in those with pre-existing gastrointestinal conditions that could delay or obstruct the passage of the tablet, such as bowel strictures or peptic ulcer disease. In the older adult population, caution is noted due to the greater likelihood of decreased kidney and heart function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Litocid overdose centers on the immediate and potentially fatal effects of Hyperkalemia (excess potassium in the blood). Documented overdose presentations often include initial nonspecific symptoms such as listlessness, muscle weakness, mental confusion, and tingling of extremities. Gastrointestinal symptoms like nausea and abdominal pain may also be present.


Severe Outcomes and Emergency Action

The most severe outcome documented in regulatory labeling is that uncontrolled hyperkalemia can rapidly lead to cardiac arrest and cardiovascular collapse. Due to this critical risk, the patient must seek immediate medical attention. If overdose is suspected, official instructions mandate that you contact a Poison Control Center or Emergency Room at once.

Specific to the extended-release formulation, regulatory documents identify the risk of localized injury, including gastrointestinal lesions and bleeding. If severe vomiting, abdominal pain, or evidence of bleeding occurs, the product should be discontinued immediately and the possibility of bowel obstruction investigated by a healthcare provider.

Treatment for hyperkalemia is symptomatic and supportive, often requiring Electrocardiographic monitoring and procedures such as intravenous administration of dextrose and insulin or use of exchange resins. High-risk populations, such as those with chronic renal failure, face a heightened probability of severe overdose.

Therapeutic Uses of Litocid

What Litocid Treats: Main Uses and Benefits

The medication Litocid (Potassium Citrate) is a long-term preventative therapy used to manage chronic metabolic conditions that cause the formation of kidney stones. It is commonly used for the management of renal tubular acidosis (RTA) with calcium stones, uric acid lithiasis (with or without calcium stones), and hypocitraturic calcium oxalate nephrolithiasis of any origin.


Preventing Recurrence in Calcium Oxalate and Uric Acid Stone Disease

This medication is commonly used to address the chronic metabolic and chemical risk factors that lead to the repeated formation of kidney stones, specifically those composed of calcium oxalate and uric acid lithiasis. The key benefit is that it provides support that helps ease the overall symptom burden associated with the risk of new stone formation, which may assist with maintaining functional stability and supports patients during difficult episodes associated with recurrence.

“It is commonly used to help maintain a sense of stability when symptoms are more noticeable.”


Management of Underlying Urinary Chemical Imbalances

Litocid is applied in addressing pathological patterns of urine chemistry, particularly hypocitraturia (low urinary citrate) and chronically acidic urine ( low pH). By correcting these sustained systemic imbalances, the medication is applied in addressing the chemical environment that contributes to stone formation, and is applied in addressing the chemical environment to help manage the presence of uric acid crystals, providing support that helps ease the overall symptom burden in conditions like Renal Tubular Acidosis.


Quick Fact: Support for Recurrent Nephrolithiasis Litocid is relevant in conditions characterized by periods of heightened symptoms associated with recurrence, supporting the patient with symptomatic relief during periods of heightened discomfort by addressing the underlying urinary chemistry.

Regulatory References

  1. DailyMed FDA Label

Eligibility and Restrictions for Use

Litocid, which contains potassium citrate, is primarily indicated for patients with calcium kidney stones who have low levels of citrate in their urine. It is also used in cases of distal renal tubular acidosis and metabolic acidosis associated with chronic kidney failure, provided there is no severe reduction in daily urine output and no hyperkalemia. Furthermore, it may be used to address potassium deficiency and other conditions that require chronic urine alkalinization.


Contraindications (Who cannot use Litocid)

Litocid is not suitable for everyone. It is generally contraindicated in individuals with:

  • Hyperkalemia (high blood potassium levels)
  • Severe renal impairment (chronic renal failure, particularly in moderate to terminal stages, or a glomerular filtration rate below 0.7 mL/kg/min)
  • Urinary tract infections
  • Alkalosis (especially metabolic alkalosis)
  • Phosphate-ammonium-magnesium (struvite) kidney stones
  • Active peptic ulcer disease or history of gastrointestinal bleeding
  • Conditions that slow the passage of the tablet through the digestive tract (e.g., intestinal obstruction)
  • Hypersensitivity to the active substance or any excipients.

Specific caution and medical supervision are required for patients who are pregnant, breastfeeding, or have mild renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Litocid (Potassium Citrate) primarily identifies interactions based on its potassium content and its extended-release solid dosage form. Co-administration with certain agents is strictly restricted.


Contraindicated and High-Risk Combinations

Classification Interacting Substances Interaction Description (Regulatory Basis)
Contraindicated Potassium-sparing diuretics (e.g., Amiloride, Spironolactone, Triamterene) Simultaneous use is prohibited due to the severe, additive risk of hyperkalemia (elevated serum potassium), which can lead to cardiac arrest.
Contraindicated Drugs that slow gastrointestinal (GI) transit (e.g., Anticholinergics) Prohibited with the solid oral formulation as slowing GI movement raises the risk of localized GI irritation, ulceration, and potential obstruction.
Caution Required ACE Inhibitors, ARBs, NSAIDs These medicinal product classes can increase serum potassium levels, contributing to the pharmacodynamic risk of hyperkalemia when combined.

Pharmacokinetic and Excretion Effects

The urinary alkalinization effect of the medicine can alter the renal clearance of other drugs. For instance, basic drugs such as Amantadine, Quinidine, and Flecainide may have reduced excretion, which can increase their concentration or effect in the body. Conversely, the renal clearance of acidic drugs may be increased.

Population-Specific Notes

The danger of interaction-related hyperkalemia is specifically noted to be heightened in patient populations with impaired potassium excretion mechanisms, including those with chronic renal failure or severe myocardial damage. The product is also contraindicated in patients with renal insufficiency (glomerular filtration rate <0.7 mL/ kg/ min) due to associated risks.

Mechanism of Action

Mechanism of Action: Urinary Chemoprophylaxis

Litocid exerts its effect by two primary, interrelated actions within the urinary system. First, the systemic metabolism of the citrate component generates an alkaline load (bicarbonate). This action modulates the body's acid-base balance, leading to an increase in the urine's pH level. This resultant urinary alkalization increases the solubility of acidic minerals, decreasing the thermodynamic stability required for crystal formation.

Second, the excreted citrate anion functions as a chelating agent by binding to free calcium ions ( Ca^2+) in the urine. This action, alongside the direct role of citrate as a crystallization inhibitor, impedes the initial formation (nucleation) and growth of mineral structures. The drug also influences renal tubule transport, reducing the reabsorption of endogenous citrate, thereby increasing the net amount of the inhibitory agent excreted. This combined molecular cascade alters the overall supersaturation of urine, promoting a stable chemical profile.

Dosage and Administration Information

How to Use Litocid

The administration of Litocid (Potassium Citrate) involves specific procedures focused on the proper use of the extended-release formulation to manage chronic urinary conditions. The medication is an oral treatment intended for long-term use.


Official Administration Guidelines

Category Instruction Details
Route of Administration Oral intake via tablet.
Standard Dosing Initial dosing ranges from 30 mEq to 60 mEq daily, depending on the baseline level of urinary citrate. The maximum recommended dose is 100 mEq per day.
Frequency Doses are divided and administered two or three times per day (b.i.d. or t.i.d.).
Timing with Meals Must be taken with meals or within 30 minutes after meals or a bedtime snack.

Key Procedural Requirements

The integrity of the extended-release tablet must be maintained during use. The tablets must be swallowed whole with sufficient liquid; they must not be crushed, chewed, or sucked. This requirement is critical for the controlled release of the active ingredient.

Dosage Adjustment and Monitoring

Dosing with Litocid is titrated (adjusted) over time based on specific, periodic measurements of 24-hour urinary citrate levels and urinary pH. The goal is to reach a urinary pH between 6.0 and 7.0 and a target citrate concentration of over 320 mg/day. When a dose adjustment is necessary, this is preferably done with the evening dose.

Population-Specific Use

While no explicit dose adjustment is typically required for older adults, the safety and efficacy in the pediatric population have not been established.

Recent Clinical Evidence

This overview summarizes the research that has been conducted to study the effects of Litocid (Potassium Citrate) in people with specific types of kidney stone conditions, focusing on the types of trials performed and the outcomes measured by researchers. This information is drawn from regulatory and peer-reviewed scientific sources and does not provide clinical advice or recommendations.

Calcium Oxalate Stone Prevention

Research for recurrent calcium oxalate stone formation is based on Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies involved adult patients with a history of stone formation and documented hypocitraturia (low urinary citrate). Researchers measured the frequency of new stone formation or recurrence and monitored chemical changes. Trials reported patterns showing that the therapy was associated with increased 24-hour measurements of urinary citrate and urinary pH in the studied populations. Evidence remains limited for certain patient subgroups, and there are questions regarding how the potential for increased urinary pH was studied in relation to the formation risk of other stone types, such as calcium phosphate.

Uric Acid Stone Disease and Dissolution

The evidence for Litocid in exploring uric acid stone disease is primarily derived from clinical trials and observational cohort studies in adults diagnosed with the condition. A key goal was to monitor chemical markers and measure the increase in urinary pH to specific target ranges relevant for uric acid solubility. Studies have explored the potential effect on existing stones, with some trials reporting measurements associated with reduction in size or dissolution. A limitation is the lower volume of large-scale, placebo-controlled RCTs specifically targeting long-term prevention compared to the evidence for calcium stones.

Evidence Gaps and Uncertainty

Studies for Renal Tubular Acidosis (RTA) are often based on smaller Clinical Series and Observational Studies, where researchers monitored the effect on systemic acidosis and specific urine chemistry markers, including the restoration of urinary citrate levels. Overall, comparative evidence is lacking in some areas, and data for certain patient groups remain insufficient, particularly for pediatric populations. The study results apply only to the specific populations studied, and long-term data regarding the effect on the potential formation of less common stone types are not fully established.

Key Studies & References

  1. Urocit-K (Potassium Citrate Extended-Release Tablets) Prescribing Information (FDA Label)
  2. Potassium Citrate: Treatment and Prevention of Recurrent Calcium Nephrolithiasis
  3. Oral Dissolution Therapy of Uric Acid Stones: A Systematic Review
  4. dRTA: How is it Treated? - National Kidney Foundation

Frequently Asked Questions (FAQ)

Common questions about Litocid (FAQ)

Q: How long until I feel Litocid actually starting to work?

A: Studies and official information indicate that the increase in the targeted chemical, urinary citrate, typically begins within the first hour after taking a single dose. The increase in citrate levels from a single dose typically lasts for about 12 hours. However, the overall success of the treatment is measured by a healthcare provider through periodic monitoring of chemical markers like urinary citrate levels and pH.

Q: What are the most common side effects people report with Litocid?

A: According to official regulatory documents, the most common adverse reactions reported often involve the gastrointestinal (GI) system. These common effects include upper abdominal pain, nausea, vomiting, diarrhea, and indigestion (dyspepsia).

Q: Is it normal to have mild nausea when starting Litocid?

A: Yes, regulatory documents classify nausea and vomiting as Very Common or Common adverse reactions. To help minimize this potential gastrointestinal discomfort, the official administration guidelines strictly require that the medication be taken with meals or a bedtime snack.

Q: How quickly does Litocid get out of your system after stopping it?

A: The drug's citrate component is quickly processed by the body and converted into bicarbonate. Less than 5% of a dose is typically excreted unchanged in the urine. The rise in urinary citrate from a single dose usually lasts for about 12 hours.

Q: What should I do if the side effects of Litocid bother me?

A: If serious symptoms occur while taking this medication, immediate medical help is needed. Official patient safety instructions list symptoms such as bloody or tarry stools, severe stomach pain, or severe vomiting as signs of a serious problem that requires prompt attention.

Q: What happens if I miss a dose of Litocid?

A: If a dose is missed, official information recommends taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular schedule. Official guidance advises against taking a double dose.

Q: Is there a generic version of Litocid available?

A: Yes, the active ingredient in Litocid, Potassium Citrate, is available as a generic extended-release tablet. Generic versions must meet the same quality and effectiveness standards set by the Food and Drug Administration (FDA) as the brand-name product.

Q: Why do some people need to take Litocid for months?

A: The medication is officially intended for long-term use. The purpose is to achieve and continuously maintain a specific chemical profile in the urine—measured by urinary pH and citrate levels—as a strategy for the chronic management and prevention of recurring kidney stone formation.

Q: Does Litocid affect your mood or cause anxiety?

A: Mood changes or anxiety are not listed as common side effects of Litocid. However, severe potassium intoxication, or hyperkalemia, is a serious risk associated with this medication. Symptoms of hyperkalemia can include mental confusion and listlessness.

Q: Why do some people say Litocid caused them stomach upset?

A: Stomach upset is a recognized and common adverse reaction, with symptoms like abdominal discomfort, nausea, vomiting, and diarrhea frequently listed in regulatory documents. Furthermore, because Litocid is an extended-release solid tablet, there is a documented risk of serious gastrointestinal lesions, such as ulceration or bleeding, which could also cause discomfort.

Q: Can people with diabetes safely use Litocid?

A: Official regulatory documents indicate that the product is strictly contraindicated in patients with conditions that predispose them to high potassium levels, such as uncontrolled diabetes. Patients with controlled diabetes are typically advised to use the medication with caution and close medical supervision due to the inherent risks.

Q: Are there any known interactions between Litocid and alcohol (informational)?

A: The official interaction sections of the product label do not list alcohol as a specific interaction that is prohibited or contraindicated. However, patient information often generally advises discussing the use of alcohol with a healthcare professional.

Q: Is Litocid safe to use during pregnancy (high-level, non-advisory)?

A: Specific caution and medical supervision are required for patients who are pregnant or breastfeeding. The official label notes that the safety and effectiveness of the medication have not been fully established for use during these periods.

Q: Can children or teenagers be prescribed Litocid?

A: The official label confirms that the safety and effectiveness of Litocid in the pediatric population (children and teenagers) have not been established through regulatory studies. Official information states the medication is for use only as directed by a healthcare professional.

Q: Is it common to feel a little dizzy after taking Litocid?

A: Dizziness is not listed as a common side effect of the medication. However, feeling lightheaded or dizzy can be a symptom of severe hyperkalemia (high potassium levels), which is a serious adverse reaction that requires immediate medical attention.

Q: Are there any restrictions on driving or operating machinery while on Litocid?

A: Driving restrictions are not explicitly listed in the US FDA label. However, serious potential side effects, such as hyperkalemia, can cause symptoms like mental confusion or dizziness, which may affect a person's ability to safely drive or operate machinery.

Q: Why is Litocid sometimes given with other medications?

A: The product is officially indicated as a 'valuable adjuvant,' meaning an addition, when administered alongside uricosuric agents in the treatment of gout. This is done to ensure the urine remains alkaline, as uric acid crystals tend to form more readily in acidic urine.

Q: Does Litocid interact with herbal supplements like St. John's Wort?

A: The official label does not specifically list St. John's Wort as an interacting substance. Official information generally advises informing a healthcare provider of all supplements to help monitor for potential interactions, given the drug's potassium content and systemic alkalizing effect.

Q: Are allergic reactions to Litocid rare?

A: While allergic reactions, such as a skin rash or hives, have been documented in official reports, the specific frequency is often classified as 'Not Known' or uncommon. A rash is not listed among the Very Common or Common side effects.

Q: Does Litocid interfere with sleep?

A: Sleep disturbances are not listed among the common side effects of Litocid. Furthermore, the medication is frequently recommended to be taken at bedtime to ensure round-the-clock urinary alkalization.

Q: Is it normal for my urine to change color when taking Litocid?

A: No official color change to the urine itself is listed as an expected effect of taking Litocid. However, because it is an extended-release tablet, the inert outer shell of the tablet may sometimes pass through the digestive tract and be visible in the stool, which is a normal occurrence.

Q: Can Litocid affect the results of common lab tests?

A: Yes, Litocid can affect lab results. Therapy with this medication requires periodic monitoring of various blood markers, including serum electrolytes (potassium, sodium, chloride), serum creatinine, and a complete blood count. These tests are essential to safely guide the treatment.

Q: Does Litocid work better if you take it at a specific time of day?

A: Doses are divided and administered two or three times per day, and taking it with a meal or snack is a required part of the instruction. Official documentation also notes that when a dose adjustment is necessary, this change is preferably made with the evening dose.

Q: Can you take Litocid with common vitamins like C or D?

A: The official interaction lists generally do not specifically name common vitamins like C or D. Official information generally advises informing a healthcare provider of all supplements to check for any potential interactions before the medication is started.

How should Litocid be stored and disposed of?

The storage and disposal of Litocid (Potassium Citrate Extended-Release Tablets) are governed by official requirements to maintain product stability and ensure public safety.

Required Storage Conditions

Litocid must be stored at controlled room temperature, typically 20 to 25 C (68 to 77 F), and must be kept from freezing or exposure to excessive heat. The container must be tightly closed to protect the product from moisture and direct light, which is essential for maintaining product integrity. A mandatory requirement is to keep this medicine out of the reach of children.

Official Disposal Instructions

Unused or expired Litocid should be disposed of by taking it to an authorized drug take-back program. If a program is unavailable, follow the procedure of mixing the product with an undesirable substance (such as dirt or coffee grounds) and placing it in a sealed container before discarding it in the household trash. The medicine must not be discharged into drains or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Litocid found in:

A-Z Index: